Form 4: Sonnet BioTherapeutics CBO Stephen McAndrew Granted 6,000 Restricted Stock Units

Sonnet BioTherapeutics Holdings, Inc. Chief Business Officer Stephen J. McAndrew was granted 6,000 restricted stock units, which are set to vest by early 2026 or upon a change in control.

Summary

• Stephen J. McAndrew, Chief Business Officer of Sonnet BioTherapeutics Holdings, Inc. (SONN), was granted 6,000 restricted stock units (RSUs) on July 11, 2025.
• These RSUs will be settled in shares of common stock, par value $0.0001.
• The RSUs are scheduled to vest 100% on the earlier of January 8, 2026, or the date of a 'Change in Control' as defined under the Issuer's 2020 Omnibus Equity Incentive Plan.
• Following this transaction, Stephen J. McAndrew beneficially owns 6,446 shares, which includes these unvested restricted stock units.
• All reported amounts reflect the company's 1:22 reverse stock split effective August 31, 2023, and a subsequent 1:8 reverse stock split effective September 30, 2024.

Sentiment

Score: 6

Explanation: The document reports a standard executive compensation grant, which is a neutral to slightly positive event as it indicates management retention and alignment of interests, without significant negative implications.

Positives

• The grant of restricted stock units serves as an incentive for the Chief Business Officer, aligning his interests with long-term shareholder value.
• Equity compensation is a common tool for executive retention, encouraging key personnel to remain with the company.

Negatives

• The issuance of new shares upon vesting of RSUs could lead to minor dilution for existing shareholders, although the number of units granted is relatively small.

Future Outlook

The vesting schedule for the restricted stock units indicates a future commitment to the Chief Business Officer, with full vesting expected by early 2026 or upon a change in control, aiming to retain key management.

Industry Context

The grant of restricted stock units is a standard practice in the biotechnology and pharmaceutical industries for executive compensation, aiming to attract, retain, and incentivize key talent by aligning their financial interests with the company's performance and long-term growth.

Comparison to Industry Standards

• Restricted stock unit grants are a widely adopted form of equity compensation for executives across various industries, including biotechnology, serving as a common mechanism for long-term incentives and retention.
• The vesting schedule, tied to a specific date or a change in control, is typical for such grants, providing a clear timeline for the executive to earn the shares.
• The practice of adjusting share counts for reverse stock splits is standard procedure to ensure accurate reporting of beneficial ownership following corporate actions.

Related Party Transactions

• The grant of 6,000 restricted stock units to Stephen J. McAndrew, the Chief Business Officer, constitutes a transaction with a related party (an executive officer) as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting of the RSUs, but the grant aims to align executive interests with shareholder value.
• Employees (specifically the CBO): Provides a significant long-term incentive and retention mechanism.

Next Steps

• The restricted stock units are expected to vest on January 8, 2026, or earlier upon a 'Change in Control'.

Key Dates

Keywords

Sonnet BioTherapeutics, SONN, Restricted Stock Units, RSU Grant, Executive Compensation, Insider Transaction, SEC Form 4, Stephen J. McAndrew, Chief Business Officer, Equity Incentive Plan, Reverse Stock Split